Literature DB >> 20828816

Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms.

Emmanouil Spanoudakis1, Ioanna Bazdiara, Despoina Pantelidou, Ioannis Kotsianidis, Vasilios Papadopoulos, Dimitrios Margaritis, George Xanthopoulidis, Eleftherios Moustakidis, Stamatia Mantzourani, George Bourikas, Costas Tsatalas.   

Abstract

Telomere exhaustion and increased telomerase activity are associated with the acquisition of aggressive molecular events in a variety of haematological malignancies. In Philadelphia chromosome negative myeloproliferative neoplasms (Ph(neg)MPN's), telomere dynamics during clonal evolution of these diseases have not yet been fully elucidated. Herein we demonstrated that telomere shortening is a global phenomenon in Ph(neg)MPN's, irrespective of disease phenotype, treatment administration and JAK2V617F mutational status but the presence of additional cytogenetic abnormalities further affects them. Consistent with the above finding, TA was upregulated in CD34+ haemopoietic progenitors from almost all Ph(neg)MPN subgroups compared to healthy donors. Moreover, TL below the cut-off value of 27% could predict disease progression in Ph(neg)MPN patients (PFS at 5 years 39% vs 81%). Thus, TL emerges as a new prognostic marker in Ph(neg)MPN, reflecting probably the genetic instability of highly proliferating MPN clones.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20828816     DOI: 10.1016/j.leukres.2010.07.042

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

1.  Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.

Authors:  Chiara Elena; Elisa Rumi; Monica Portolan; Matteo G Della Porta; Cristiana Pascutto; Francesco Passamonti
Journal:  Haematologica       Date:  2011-08       Impact factor: 9.941

2.  Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.

Authors:  G Mosoyan; T Kraus; F Ye; K Eng; J D Crispino; R Hoffman; C Iancu-Rubin
Journal:  Leukemia       Date:  2017-03-08       Impact factor: 11.528

3.  Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations.

Authors:  Samah Alimam; Donal P McLornan; Jie Jiang; Deepti Radia; Ghulam J Mufti; Claire N Harrison
Journal:  Haematologica       Date:  2017-11-30       Impact factor: 9.941

Review 4.  Pharmacotherapy of Myelofibrosis.

Authors:  Douglas Tremblay; Bridget Marcellino; John Mascarenhas
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 5.  Association between telomere length and survival in cancer patients: a meta-analysis and review of literature.

Authors:  Xinsen Xu; Kai Qu; Qing Pang; Zhixin Wang; Yanyan Zhou; Chang Liu
Journal:  Front Med       Date:  2016-05-16       Impact factor: 4.592

6.  The Association between Telomere Length and Cancer Prognosis: Evidence from a Meta-Analysis.

Authors:  Chunli Zhang; Xiaohua Chen; Lu Li; Ying Zhou; Chao Wang; Shuxun Hou
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

7.  Ruxolitinib therapy and telomere length in myelofibrosis.

Authors:  G Caocci; M Greco; G Delogu; C Secchi; A Perra; S Ghiani; F Orru; A Vacca; F Galimi; G La Nasa
Journal:  Blood Cancer J       Date:  2016-10-07       Impact factor: 11.037

Review 8.  Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.

Authors:  Theresa Vasko; Andrea Kaifie; Matthias B Stope; Thomas Kraus; Patrick Ziegler
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

9.  TERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations.

Authors:  Jenny Dahlström; Tiantian Liu; Xiaotian Yuan; Leonie Saft; Mehran Ghaderi; Ya Bin Wei; Catharina Lavebratt; Ping Li; Chengyun Zheng; Magnus Björkholm; Dawei Xu
Journal:  Ann Hematol       Date:  2016-08-25       Impact factor: 3.673

10.  Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms.

Authors:  Michal Bar-Natan; Ronald Hoffman
Journal:  Expert Rev Hematol       Date:  2020-10-19       Impact factor: 2.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.